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A large body of evidence suggests that the use of aspirin and other non-steroidal anti-inflammatory 
drugs (NSAIDs) reduces the risk of colorectal cancer.  However, because their use can also lead to 
side effects such as gastrointestinal bleeding, NSAID use is not recommended for colorectal cancer 
prevention among the general population.  Of great interest for researchers, then, is identifying 
subgroups of people for whom the benefits of colorectal cancer chemoprevention outweigh the risk 
of side effects.  To identify these groups, Ms. Wendy Wang and Dr. Emily White and colleagues in 
the Public Health Sciences Division evaluated the association between NSAID use and colorectal 
cancer risk across a range of subgroups with differing risk factors.  In a recent article in Cancer 
Epidemiology, Biomarkers, & Prevention, the authors report that the protective effect was consistent 
across these various subgroups, suggesting that the beneficial role of NSAIDs on colorectal cancer 
risk is unmodified by these additional risk factors. 
Chronic inflammation is an established risk factor for colorectal cancer, and NSAIDs are thought to 
lower this risk by inhibiting inflammatory pathways and reducing inflammation.  In addition to 
inflammation, there are a large number of other risk factors that have been associated with 
colorectal cancer risk.  These include factors such as obesity, physical inactivity, smoking, family 
history, and high consumption of red meat and alcohol.  While it is suspected that some of these risk 
factors might also impact risk by increasing inflammation, their interaction with NSAID use are 
unclear.  If NSAID use were to mitigate the increased risk due to some of these additional factors, 
then subgroups of people with higher risk could be more appropriately targeted for chemoprevention 
strategies. 
To identify such groups, the authors tested the interaction between NSAID use and these various 
risk factors on colorectal cancer risk using data from the VITamins and Lifestyle (VITAL) study.  This 
large cohort study of roughly 75,000 western Washington residents provided detailed prospective 
information on a large range of exposures.  Incident colorectal cancer cases were identified through 
the Surveillance, Epidemiology, and End Results (SEER) cancer registry.  Cox regression was used 
to evaluate the association between NSAID use in the 10 years prior to baseline and development of 
colorectal cancer during follow-up (average 8.4 years). 
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Testing across these subgroups, the authors found that any type of NSAID use for at least 4 days a 
week for at least 4 years was associated with a 42% lower risk of colorectal cancer (p-trend < 
0.001).  This protective association was consistent among subgroups defined by additional risk 
factors, with reductions in risk ranging from 32% to 56% within each subgroup (p-trend < 
0.05).  Though not statistically significant, high NSAID use appeared to have a greater risk reduction 
among men, participants who were obese, and regular alcohol drinkers.  Further evaluations looking 
at cancer site and cancer stage also suggested that NSAID use was associated with a lower risk of 
proximal colon cancer compared to distal colon cancer, and distant stage colorectal cancer 
compared to local stage. 
"Our results suggest that use of aspirin or other NSAIDs has a generally beneficial role in colorectal 
cancer prevention, largely unmodified by other lifestyle factors," said lead author Ms. Wendy 
Wang.  "However, the differential effects by colorectal cancer subsites may indicate potential 
chemopreventive pathways of NSAID use. Our study, along with previous observational studies, did 
not have sufficient power to detect small differences in the effects of NSAIDs on colorectal cancer 
risk between subgroups of the population. Therefore, we aim to replicate this systematic evaluation 
of effect modifiers between NSAID use and colorectal cancer risk in the Genetic Epidemiology of 
Colorectal Cancer Consortium (GECCO), a large consortium of cohort and case-control studies for 
colorectal cancer." 
Other PHS researchers contributing to this project were Drs. Ulrike Peters and John Potter. 
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Image provided by Ms. Wendy Wang 
Generic non-steroidal anti-inflammatory drugs (NSAIDs) are readily 
accessible over the counter. 
 
